A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Reprogramming Induced Pluripotent Stem Cell Lines from Frozen Buffy Coat Samples

470 views

⸱

DOI:

10.3791/70522

⸱

April 10th, 2026

 ,  ,  ,  ,  ,  ,  ,  ,  , 
1Center for Molecular Medicine, University of Georgia, 2Interdisciplinary Neuroscience, University of Georgia, 3Department of Biochemistry and Molecular Biology, University of Georgia, 4Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, 5Division of Pediatric Endocrinology, Emory University School of Medicine, 6Dysautonomia Center, New York University Langone Health, 7Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 8Stem Cell Core, Columbia Stem Cell Initiative, Columbia University, 9Department of Cellular Biology, University of Georgia

In This Article

Summary

The current protocol details steps for troubleshooting induced pluripotent stem cell (iPSC) derivation from patient samples’ peripheral blood mononuclear cells (PBMCs) that have been difficult to reprogram following the manufacturer’s instructions. This protocol is specific to frozen buffy coat samples but may also be applied to the reprogramming of purified PBMCs.

Abstract

Human pluripotent stem cells (hPSCs) are a valuable tool for disease modeling. Further stem cells can be reprogrammed from adult somatic cells, called induced pluripotent stem cells (iPSC). iPSC technology allows for the evaluation of specific study participants and populations and ventures into personalized medicine. Blood is routinely taken and cryopreserved for research purposes. These samples are processed either as buffy coats, a blood sample containing white blood cells and platelets, or as peripheral blood mononuclear cells (PBMCs), which represent a more purified population of white blood cells without eosinophils, basophils, platelets, or red blood cells. Both are a readily available and relatively non-invasive source for reprogrammable somatic cells. Several reports detail reprogramming from PBMCs, whereas only one describes this process from frozen buffy coats. Recent experience revealed PBMC reprogramming protocols available in the literature and from manufacturers to be unsuccessful when applied to frozen buffy coat samples, necessitating the adaptations and troubleshooting strategies described here. For many researchers, who employ iPSC technologies, it is imperative to have thorough protocols with a high success rate, especially in cases, where patient samples may contain only few cells, are obtained in wide time intervals, are from limited participant pool, or are otherwise highly valuable. Here, checkpoints and troubleshooting strategies are identified to increase the chance of reprogramming human frozen buffy coats or purified PBMCs. Ultimately, this protocol will allow researchers to identify predictors of reprogramming success and strategize alternative approaches to improve the chances of successful iPSC derivation.

Introduction

Human pluripotent stem cell (hPSC) technology is an easily scalable and renewable source of human cells that can be differentiated into any cell type in the body, allowing researchers to investigate cell and tissue types that are hard to obtain or inaccessible in patients. Further, induced pluripotent stem cells (iPSCs) can be derived directly from patient somatic cells1. This allows for the differentiation of patient-specific cell types of interest, an invaluable tool for disease modeling and drug discovery. Thus, rigorous, reproducible and successful methods to reprogram somatic cells into iPSCs are critical.

Fibroblasts, urine cells, and blood cells2,3, each with their own limitations, are some of the most frequently used somatic cell sources for iPSC derivation. Fibroblasts, historically the most popular choice for reprogramming3, are not very easily obtained, requiring a somewhat invasive skin biopsy. Reprogrammable cells can be derived from urine samples, which are easy to obtain and non-invasive, but the reprogramming process must begin with fresh samples up to 48 h after collection4. Blood offers a great source for reprogrammable cells, as it is minimally invasive to obtain and readily available. There are many available reprogramming protocols from peripheral blood mononuclear cells (PBMCs), blood cells with a single nucleus including lymphocytes, monocytes and natural killer cells5. Because PBMCs are less dense than other blood cells, they can be isolated/purified from freshly isolated whole blood samples through density gradient centrifugation5. Alternatively, upon centrifugation, whole blood separates into three distinct layers: plasma, buffy coat, and red blood cells6. Buffy coats contain PBMCs as well as platelets and some erythrocytes. However, PBMCs are less readily available in most biobanks, whereas whole blood or buffy coats are abundant and accessible7. Despite the availability of buffy coats in biobanks and the presence of reprogrammable PBMCs in these samples, very few protocols detail reprogramming from frozen buffy coats8, leaving this an untapped resource.

Currently, there are many published protocols1,8,9 and commercially available kits10 to streamline reprogramming; however, they do not deeply troubleshoot how to maximize success for patient donor cells that are hard to reprogram. It is commonly accepted that some cells just won’t reprogram, and when this happens, many researchers may try with a different donor cell type or a different patient. However, this may not be a viable option for many researchers or patient populations. Unlike previously published protocols8,9, this protocol includes a guide with check points and criteria, based on which to predict reprogramming success and takes a unique approach by purifying frozen buffy coats with density gradient centrifugation upon thawing.

The process begins with drawing blood from chosen individuals and isolating either PBMCs or buffy coats. For new experiments, this is likely to include recruiting new donors who will undergo fresh blood draws under IRB approval and with a proper consent form. The next step is somatic cell expansion, in which frozen blood cells are thawed and cultured under conditions that promote the proliferation of hematopoietic stem cells and erythroid progenitors, the blood cells that are the best candidates for reprogramming11. After 10–14 days, cells should be ready for reprogramming, as evidenced by a distinct morphology which is not discussed in previous protocols, and are then transduced by inoculation with a Sendai virus carrying the Yamanaka factors Oct4, Sox2, c-Myc, and Klf41. Following transduction, cells will begin expressing the Yamanaka transcription factors and will return to a pluripotent state, again denoted by a distinct morphological change and proliferation into stem cell colonies. Emerging colonies are then individually picked, expanded, and cryopreserved. After ten passages, characterization by confirmation of expression of stemness markers and differentiation potential into the three germ layers validates a successfully reprogrammed iPSC line.

This protocol works best for cryopreserved buffy coats, which have been stored for < 1 month, or cryopreserved PBMCs stored for up to 2 years with at least 1 million viable cells upon thawing. However, the described checkpoints may help guide troubleshooting reprogramming from any quality blood sample. Additionally, details about adapting reprogrammed iPSCs to feeder-free conditions can be applicable to any iPSC reprogramming workflow, regardless of starting somatic cell type.

This protocol, established through hands-on troubleshooting, details reprogramming iPSCs from frozen buffy coats and identifies morphological indicators of reprogramming success, providing a workable guide to reprogramming difficult samples. Ultimately, implementing these strategies results in conservation of time, money, reagents, and samples.

Access restricted. Please log in or start a trial to view this content.

Protocol

This protocol follows the guidelines of the University of Georgia’s human research ethics committee. All human subject studies were performed according to the guidelines of the World Medical Association’s Declaration of Helsinki. Based on self-report, the volunteers did not suffer from the following diseases: cystic fibrosis, chronic obstructive pulmonary disease, tuberculosis, asthma, diabetes or acute airway infections. Volunteers of ages between 18–50 years and of both sexes were recruited. Pregnant women were excluded from the study.

1. Buffy coat or PBMC extraction and cryopreservation

Decision criteria: If the samples will be stored for a long time, it is best to choose option 2. If the reagents for PBMC purification are not available, or samples will be stored for a short period of time, option 1 is suitable.

  1. Option 1: Buffy Coat Extraction
    1. Perform a phlebotomy (vein puncture to take blood) according to WHO best practices12 and take 7–10 mL whole blood into anti-coagulant coated blood collection tubes. Keep samples on ice.
    2. Transfer 7–10 mL of whole blood to a 15 mL conical tube. Spin blood down using a swinging bucket centrifuge at 200 x g for 15 min at 4 °C with the brakes off. This should form 3 layers with yellow plasma on top, the white buffy coat layer in the middle, and the red erythrocytes at the bottom.
    3. Collect the plasma using a sterile serological pipette without disturbing the buffy coat layer. Discard the plasma. Transfer the white buffy coat layer to a fresh 15 mL conical tube (approximately 1–2 mL).
      CAUTION: Dispose of the plasma in the appropriate biohazardous waste bin.
      NOTE: Some plasma contamination of the buffy coat is fine as it aids in recovering after thawing.
    4. Add DMSO to the buffy coat such that the final composition is 10% DMSO v/v and freeze in cryovial (1 mL/vial) at -80 °C immediately. The day after, move the vials to liquid nitrogen for long-term storage.
      NOTE: As an example, for 2 ml of buffy coat, add 200 µl of DMSO, mix well, then aliquot into 2 vials. This typically results in 1–3 frozen vials per sample.
  2. Option 2: PBMC Purification
    1. Perform a phlebotomy (vein puncture to take blood) according to WHO best practices12 and take 7–10 mL whole blood into anti-coagulant-coated blood collection tubes. Keep samples on ice.
    2. Add 4 mL density gradient solution 1 into a fresh 15 mL conical tube. Carefully layer 4 mL of blood on top of the density gradient solution 1.
    3. Centrifuge using a swinging bucket centrifuge at 400 x g at RT for 30 min, turning the brakes off. This will result in plasma in the top layer, PBMCs in the middle layer, and the remainder of the blood will be in the bottom.
    4. Collect the PBMC fraction into a fresh 15 mL conical tube, then wash it 2–3 times with 1x PBS by centrifuging in a swinging bucket centrifuge at 350 x g at RT for 5 min with the brake on. Discard the supernatant. To skip cryopreservation and immediately begin reprogramming, proceed to step 2.3.4.
      CAUTION: Dispose of the supernatant in the appropriate biohazardous waste bin.
    5. Resuspend pellet in cryopreservation media (90% serum and 10% DMSO) and freeze in cryovial (1 mL/vial) at -80 °C immediately. The day after, move the vials to liquid nitrogen for long-term storage.
      NOTE: PBMC isolating blood collection tubes may be used rather than density gradient centrifugation for PBMC purification from fresh blood. It is also possible to cryopreserve using commercially available alternate freezing mediums. Typical yield is 1–4 frozen vials per sample.

2. Prepare samples for somatic cell expansion

  1. Media preparation
    1. Prepare Expansion Media (EM)9 by aliquoting 45 mL of EM base. Add 127.8 µL L-ascorbic acid (50 µg/mL from 100 mM stock) and 450 µL penicillin-streptomycin (100x stock).
    2. Prepare EM + cytokines13 to 4 ml EM, add 2 µL stem cell factor (SCF) (50 ng/mL from 100 µg/ml stock), 2 µL interleukin-3 (IL-3) (10 ng/mL from 20 µg/mL stock), 16 µL erythropoietin (EPO) (2 U/mL from 500 U/mL stock), 4 µL insulin-like growth factor 1 (IGF1) (40 ng/mL from 40 µg/ml stock), and 4 µL dexamethasone (1 µM from 1 mM stock). Use EM + cytokines on the same day it is prepared.
      NOTE: Alternative commercial expansion medium systems may be used.
  2. Option 1: PBMC Purification from Frozen Buffy Coat
    Decision criteria: if option 1 in step 1 was chosen (i.e. buffy coat extraction), then choose option 1 in step 2 (i.e. PBMC purification from frozen buffy coat).
    1. Retrieve density gradient solution 2 and allow to come to room temperature. Mix thoroughly by inverting the bottle. Aseptically transfer 3 mL density gradient solution 2 to a 15 mL conical tube.
    2. Prepare another 15 mL conical tube with 12 mL Dulbecco’s phosphate buffer saline (DPBS).
    3. Retrieve the vial of frozen buffy coat from the liquid nitrogen. Keep on ice until ready to thaw. Gently thaw the sample by swirling in 37 °C water bath. Remove when only a small ice crystal remains.
    4. Carefully (dropwise) transfer the contents of the vial into the conical tube containing DPBS. Rinse the vial with 1 mL of DPBS and add to the conical tube containing retrieved cells.
    5. Centrifuge using a swinging bucket centrifuge at 200 x g at RT for 10 min. Carefully remove supernatant and resuspend cell pellet in 4 mL DPBS with 1% fetal bovine serum (FBS).
    6. Gently layer the buffy coat mixture on top of the density gradient solution, being careful not to allow mixing. Centrifuge in a swinging bucket centrifuge at 800 x g for 20 min at RT with the brake off.
    7. With a pipet, remove and discard the upper plasma layer without disturbing the plasma:gradient interface. With a pipet, remove the PBMC layer at the interface (Figure 1A) and transfer to a clean 15 mL tube.
      CAUTION: Dispose of the other layers in the appropriate biohazardous waste bin.
    8. Wash the PBMCs with 3 mL EM by centrifuging at 200 x g for 10 min at RT. Carefully remove the supernatant and resuspend the pellet in 2 mL EM + cytokines. Plate in 1 well of a 12-well plate.
    9. Place the plate in the incubator at 37 °C, 5% CO2 and 20% O2.
  3. Option 2: Thawing frozen PBMCs
    Decision criteria: if option 2 in step 1 was chosen (i.e., PBMC purification), or if there is a concern that frozen buffy coats will have low viability (i.e., in storage for more than 1 month) (Figure 1B), then choose option 2 in step 2 (i.e., thawing frozen PBMCs).
    1. Prepare a 15 mL conical tube with 12 mL DPBS.
    2. Retrieve the vial of frozen PBMCs from liquid nitrogen. Keep on ice until it is ready to thaw. Gently thaw the sample by swirling in a 37 °C water bath. Remove when only a small crystal is left.
    3. Carefully (dropwise) transfer the contents of the vial into the conical tube. Be sure to retrieve all cells from the vial by rinsing the vial with 1 mL of DPBS.
    4. Centrifuge in a swinging bucket centrifuge at 200 x g at RT for 10 min. Carefully remove the supernatant and resuspend the pellet (Figure 1C) in 2 mL EM, then take 10 µL to perform trypan blue exclusion test for cell viability to obtain cell count14.
      CAUTION: Dispose of the supernatant in the appropriate biohazardous waste bin.
    5. Plate 1.0 x 106–2.0 x 106 cells/mL in 2 mL EM + cytokines in one well of a 12-well plate. Place the plate in the incubator at 37 °C, 5% CO2 and 20% O2.

3. Somatic cell expansion (1 day after thawing)

  1. Carefully remove 1 mL of spent media from each well. Spent media can be collected in another well or centrifuge tube and checked to ensure that no cells have been lost.
  2. Replace spent media with 1 mL of fresh EM + cytokines.
  3. Repeat steps 3.1 and 3.2 and take pictures of PBMCs every other day until a significant change in morphology is observed, with bright and round cells of large and small size (Figure 2A, orange and blue arrow, respectively), which are the erythroblasts, the cell type to reprogram. This will take about 10–14 days.
    NOTE: Cells that do not display these morphologies, typically lacking the larger round cells (Figure 2B), are unlikely to reprogram successfully and may be dead (Figure 2C).

4. Transduction (10–14 days after thawing)

  1. Prepare Sendai Virus
    1. Using the lot-specific titer value, calculate the volume of each virus needed for transduction of 2.0 × 105 cells using KOS: c-Myc: Klf4 with a multiplicity of infection (MOI) of 5:5:3, as recommended by the manufacturer. The equation for this calculation can be found in the product documents provided by the manufacturer.
    2. Retrieve viruses from the freezer, keeping them on ice until time to thaw. One by one, gently thaw the viruses by swirling in a 37 °C water bath.
    3. Prepare aliquots in which all three viruses are mixed at the appropriate volume for transduction of 2.0 × 105 cells at MOIs of 5:5:3. Freeze aliquots at -80 °C until ready for use.
      CAUTION: Be sure to thoroughly bleach all waste that has contacted Sendai Virus.
      ​NOTE: Manufacturer instructions recommend an actual count of cells with MOI calculation to determine volume of virus added, but the approximation of 2.0 × 105 has been successful for the purposes of this protocol. Aliquoting can be more cost effective and reduces the amount of freeze/thaw cycles for viruses.
  2. Day of Transduction (d0)
    1. If the PBMCs were not fed the day before, remove 1 mL of spent media and replace with 1 mL of fresh EM + cytokines. Thaw the virus aliquot on ice, then add directly to the well, swirl the media.
    2. Wrap the plate in parafilm and centrifuge the plate in a swinging bucket centrifuge at 350 x g at RT for 90 min. Place the plate in the incubator at 37 °C, 5% CO2, and 20% O2 overnight.
      ​CAUTION: Be sure to thoroughly bleach all waste that has contacted Sendai Virus.
  3. 1 Day after transduction (d1)
    1. Collect the cells into a 15 mL conical tube. Rinse well with 2 mL EM and check under the microscope to ensure that all cells have been collected. Centrifuge cells at 300 x g at RT for 10 min.
    2. Carefully remove supernatant and resuspend in 2 mL EM + cytokines. Place in a fresh well of a 12-well plate and return the plate to the incubator at 37 °C, 5% CO2, and 20% O2.
      CAUTION: Be sure to thoroughly bleach all waste that has come in contact with Sendai Virus.

5. Replate Transduced cells onto Feeder Cells

  1. Prepare Feeder Cell
    1. To 43.5 mL Dulbecco’s modified Eagle medium (DMEM) add 5 mL FBS (final concentration 10%), 0.5 mL minimum essential medium non-essential amino acids solution (MEM-NEAA) (from 100x stock), 50 µL 2-mercaptoethanol (55 µM from 55 mM stock), and 0.5 mL antibiotic-antimycotic (from 100x stock).
    2. Prepare gelatin-coated 6-well plates by adding 600 µL gelatin (0.1% from 2% stock) to 12 mL DPBS and distributing 2 mL per well. Incubate at room temperature for 20 min.
    3. Retrieve frozen vial of irradiated mouse embryonic fibroblasts (MEFs) and gently thaw by swirling in 37 °C water bath.
    4. Add dropwise to 15 mL conical tube containing 10 mL DPBS and rinse vial with an additional 1 mL DPBS. Centrifuge at 200 x g at RT for 5 min.
    5. Carefully remove supernatant and resuspend the cell pellet in 1 mL fibroblast media. Remove 10 µL to perform trypan blue exclusion test for cell viability to obtain the cell count14.
    6. Remove the gelatin solution from the 6-well plates and plate irradiated MEFs at 2.5 × 104 cells/cm2. Incubate in incubator at 37 °C, 5% CO2 and 20% O2 for 6–48 h.
      NOTE: Feeder cell plates must be prepared prior to replating of transduced cells. Best results have been seen when irradiated MEFs are incubated for about 2 days before replating, but incubation for at least 6 h can be sufficient.
  2. Re-plate Transduced Cells
    1. Prepare iPSC media 90 mL DMEM/F12 with 10 mL FBS (10% final concentration) , 1 mL MEM-NEAA (from 100x stock), 1 mL L-glutamine (2 mM from 200 mM stock), 1 mL penicillin-streptomycin (from 100x stock), 100 µL 2-mercaptoethanol (55 µM from 55 mM stock), and 100 µL fibroblast growth factor 2 (FGF2) (10 ng/mL from 10 µg/mL stock). Add L-ascorbic acid (50 µg/mL) fresh at each feeding.
    2. On day 3 after transduction, collect all media and cells from the transduced well into a 15 mL conical tube. Rinse well with at least 1 additional mL of EM and centrifuge in a swinging bucket centrifuge at 300 x g at RT for 10 min.
    3. Resuspend the pellet in 6 mL iPSC media. Aspirate the media from 3 wells of the plate with irradiated MEFs.
    4. Plate transduced cells onto these 3 wells of irradiated MEF (2ml/well). Incubate in incubator at 37 °C, 5% CO2 and 20% O2.

6. Maintenance until colony emergence

  1. On days 4, 5, and 6 after transduction, add 1 mL of fresh iPSC media to each well each day. This limits unnecessary disturbance of the freshly reprogrammed cells as they settle onto the feeders, while also providing them with fresh nutrients.
  2. On day 7 after transduction, remove all old media and replace with 2 mL of fresh iPSC media per well. Continue to feed with iPSC media every other day until colonies begin to emerge.
  3. Prepare hES media 78 mL DMEM/F12 with 20 mL FBS free supplement (20%), 1 mL MEM-NEAA (100x), 1 mL L-glutamine (2 mM from 200 mM stock), 1 mL penicillin-streptomycin (100x), 100 µL 2-mercaptoethanol (55 µM from 55 mM stock), and 100 µL FGF2 (10 ng/mL from 10 µg/ml stock). Add L-ascorbic acid (50 µg/mL) fresh at each feeding.
  4. Once small colonies have begun to emerge, continue maintaining the transduced cells by feeding every other day with hES media (Figure 3A).
    NOTE: Colonies will begin to appear as early as 7 days after transduction. If no colonies have emerged by three weeks after transduction, it is not likely that colonies will ever emerge.

7. Pick colonies once they have grown to a larger size (Figure 3B)

NOTE: Sometimes transduced cells undergo a morphological change that does not result in a stem cell like colony (Figure 3C). This is not considered a colony that could lead to a successful iPSC line.

NOTE: From colony emergence, iPSC lines will need to be adapted to the preferred hPSC culturing conditions of the lab. This protocol will demonstrate how iPSC lines have been adapted to feeder-free conditions, cultured on vitronectin (VTN) coated plates, fed with chemically defined and commercially available hPSC media. If colonies are not adapting well to the new conditions, they may need a gentler transition, like being picked onto feeder cells with hES media.

  1. Prepare VTN-coated plates by thawing and thoroughly mixing VTN. For a 24-well plate, prepare 12 mL of DPBS with 120 µL VTN (5 µg/mL from 500 µg/mL stock) and distribute 0.5 mL VTN solution/well. Incubate at room temperature for 1 h.
  2. Prepare hPSC medium by thawing 1 bottle of hPSC supplement at 4°C overnight. Once thawed, add 10 mL hPSC supplement to one 500 mL bottle of hPSC basal medium.
  3. Prepare the plates for picking by removing VTN solution from wells of the 24-well plate and adding 0.5 mL hPSC media with 0.5 µL Y-27632 (10 µM from 10 mM stock) to each well.
  4. Bring the new plate, the 6-well containing the transduced cells/colonies, sterile syringe needles, and a p200 pipette and tips to a dissecting microscope in sterile conditions.
  5. Place the plate containing the transduced cells and emerged colonies on the dissecting microscope and use the microscope to locate one colony to pick. Lift the lid of the plate to expose the well.
  6. Aseptically open the syringe and expose the needle. Guided by the microscope, use the needle tip to detach the colony from any surrounding feeder cells by tracing the outline of the colony with the needle.
  7. Use the needle tip to cut the colony into a few equal size pieces. If the colony pieces have not already detached from the plate, use the side of the needle to scoop or scrape them off the plate so they are floating.
    CAUTION: Discard the needle in the appropriate sharps container.
  8. With the p200, use the microscope to relocate the picked colony. Aspirate the floating colony with the pipette and transfer to a well of the prepared 24-well plate. Try to get the entire colony into the well without getting any other colonies or feeder cells.
  9. Place the plate in the incubator at 37 °C, 5% CO2 and 20% O2.
  10. Feed the picked colonies with 1 mL of hPSC medium every day until they are confluent.
    NOTE: Colonies have the potential to be genetically distinct from one another. Each well of the 24-well plate must only contain one picked colony. Each picked colony is given a distinct identifier and from here on out is treated as a different cell line from other picked colonies. For a rigorous round of reprogramming, pick at least 24 colonies and expand and characterize at least 3.

8. Expand

  1. hPSC maintenance
    1. The picked colonies are ready to split when they are large and round with glowing edges (Figure 4A). Colonies break into multiple pieces when picked. If there are multiple colonies in one well, split them before they have grown large enough to contact each other and begin to differentiate.
    2. Prepare a VTN-coated 6-well plate: For a 6-well plate, prepare 12 mL of DPBS with 120 µL VTN (5 µg/mL from 500 µg/mL stock) and distribute 1 mL VTN solution/well. Incubate at room temperature for 1 h. VTN solution can be replaced with DPBS and stored at 37 °C, 5% CO2 for a month. In the wells that will be split into, aspirate DPBS and replace with 1 mL hPSC medium.
    3. Aspirate the media from the well to split, then rinse once with 1 mL DPBS. Aspirate the DPBS and add 500 µL 0.5 mM EDTA dissociation buffer (prepared in 500 mL DPBS with 0.9 g NaCl and filter sterilized)15. Incubate at 37 °C, 5% CO2 for 2 min, until the colonies start loosening up, and cells inside each colony start to round up and detach from one another.
    4. Remove the plate from the incubator, aspirate the EDTA dissociation buffer. Using a p1000 pipette, collect the cells with 1 mL hPSC medium by gently pipetting up and down until the colonies are fully detached and slightly broken up. Transfer the 1 mL of medium and cells into the new 6-well containing 1 mL of fresh hPSC medium. This first split is done at a 1:1 splitting ratio, all cells from the original plate are carried over to the new plate.
    5. Place the cells in the incubator at 37 °C, 5% CO2 and 20% O2. Feed iPSCs daily until the well is confluent and ready to split.
      NOTE: Poor stem cell morphology (Figure 4B) may be mitigated by adjusting splitting protocol such as splitting earlier, using a shorter EDTA incubation time, or adjusting the splitting ratio.
    6. Expand into 10 cm dish.
      1. Once cells are confluent in each well of the 6-well plates, coat a 10 cm dish with VTN (7 mL DPBS with 70 µL VTN (5 µg/mL from 500 µg/mL stock), incubated for 1 h at RT).
      2. Repeat splitting protocol, this time expanding from the 6-well into the 10 cm tissue culture dish (splitting ratio 1:1). Use 7–10 mL of hPSC medium per 10 cm dish.
      3. Once cells in the 10 cm dish are confluent, repeat this splitting process (passaging). At each passage, note the passage number. Splitting ratio depends on cell morphology and density. A typical ratio is 1:10, where one tenth of the cells from the original plate are carried over to the new plate.
  2. Freezebacks and stock preparations
    1. After about 3 passages, expand into four 10 cm tissue culture dishes for early passage stocks. Once cells in the 10 cm dishes are confluent, they are ready to be frozen.
    2. Prepare cryovials and place them in the freezer to cool. Be sure the label includes the cell line, clone, passage number, and date of freeze.
    3. Prepare freezing media: 90% hPSC medium and 10% DMSO, you’ll need 1 mL/vial (3 frozen vials per 10 cm dish).
    4. Perform splitting protocol as normal, using 4 mL 0.5 mM EDTA dissociation buffer for each 10 cm dish.
    5. After EDTA incubation, aspirate EDTA. Gently add 10 mL of hPSC medium to the dish.
    6. Gently wash the cells off the dish by pipetting the media. The cells will come off the floor of the dish easily and mix in the media. Only pipette 2–5 times to gently break up colonies but avoid dissociation into single cells.
    7. Centrifuge for 5 min at 200 x g at RT. Aspirate supernatant and resuspend the cell pellet in freezing medium.
    8. Insulate and freeze immediately at -80 °C. Transfer the frozen vials to the liquid nitrogen tank for long-term storage.
    9. Freeze more stocks in the same way once the characterization has been completed.

9. Characterization of iPSCs:

  1. Expression of stemness markers. After expanding for at least 10 passages, when colonies in a 24-well are ready to be split, fix with 4% paraformaldehyde and stain by immunohistochemistry for stemness marker NANOG. It will take at least 10 passages for colonies to be Sendai Virus (SeV) negative, which can be confirmed by immunofluorescence (Figure 4C).
  2. Test pluripotency ability: Three Germ Layer Differentiations. iPSC pluripotency is confirmed by successful differentiation into each of the three germ layers. Each differentiation starts from a confluent 10 cm dish exhibiting good hPSC morphology (Figure 4A).
    1. Ectoderm16
      1. The day before the differentiation starts (day-1): Seed iPSCs on matrix-coated 24-well plates at a density of 2.6 × 105 cells/cm2 in hPSC medium with Y-27632 (10 µM final concentration) and XAV-939 (2 µM final concentration).
      2. Day 0–day 1: Feed with 1 mL/well differentiation base with LDN (100 nM final concentration), SB (10 µM final concentration), and XAV (2 µM final concentration).
      3. Day 2–day 7: Feed with 1 mL/well differentiation base with LDN (100 nM final concentration) and SB (10 µM final concentration). From d3, feed every other day.
      4. Day 8: fix with 4% paraformaldehyde and stain by immunohistochemistry for ectoderm marker PAX617 and confirm loss of pluripotency marker NANOG (Figure 4D).
    2. Mesoderm18:
      1. The day before the differentiation starts (day -1): Seed iPSCs on matrix-coated 24-well plates at a density of 2.5 × 105 cells/cm2 in hPSC medium with Y-27632 (10 µM final concentration).
      2. Day 0: Feed with DMEM/F12 with L-Ascorbic Acid (64 µg/mL final concentration), Sodium Selenite (13.6 ng/mL final concentration), Holotransferrin (10 µg/mL final concentration), chemically defined lipid concentrate (100x), and CHIR (5 µM final concentration).
      3. Day 1: Feed with DMEM/F12 with L-Ascorbic Acid (64 µg/mL final concentration), Sodium Selenite (13.6 ng/mL final concentration), Holotransferrin (10 µg/mL final concentration), chemically defined lipid concentrate (100x), and heparin (0.6 U/mL final concentration).
      4. Day 2: Fix with 4% paraformaldehyde and stain by immunohistochemistry for BRACHYURY-T19 and confirm loss of pluripotency marker NANOG (Figure 4E).
    3. Endoderm20​
      1. The day before the differentiation starts (day -1): Seed iPSCs on matrix-coated 24-well plates at a density of 1.0 × 105 cells/cm2 in hPSC medium with Y-27632 (10 µM final concentration).
      2. Day 0–day 4: On d0, wash with DPBS and feed with RPMI with L-glutamine substitute (100x), FBS (0.5% final concentration), and Activin A (100 ng/mL final concentration). From d0, feed daily with the same media.
      3. Day 5: Fix with 4% paraformaldehyde and stain by immunohistochemistry for endoderm marker SOX1721 and confirm loss of pluripotency marker NANOG (Figure 4F).
        NOTE: Differentiations were done according to previously published protocols. In our experience matrix coatings can be interchangeable.

Access restricted. Please log in or start a trial to view this content.

Results

Success of this protocol can be tracked at various stages. Table 1 offers a summary of samples on which this protocol has been performed. Starting samples, which are either cryopreserved buffy coats stored for one week or cryopreserved PBMCs, that have good sample quality upon thawing and the distinct morphological appearance after cell expansion successfully reprogrammed 6/7 times (Table 1, category 1). Two more buffy coat samples, collected and stored under similar conditions exhibited...

Access restricted. Please log in or start a trial to view this content.

Discussion

iPSC technology has immense potential in the biomedical field with regard to disease mechanism discovery, personalized medicine, and “clinical trials in a dish”22,23. Efficient and adaptable protocols for iPSC reprogramming from blood samples are key to unlocking the grand potential of iPSC technology as they are easy to collect and often readily available in biobanks. While there are many published protocols that detail reprogramming from purified PB...

Access restricted. Please log in or start a trial to view this content.

Disclosures

We declare that the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgements

Human subjects were recruited and provided informed consent for blood donation according to the IRB protocol UGA# 2012-10769-06, NYU# s21-01701, Emory# 2024P008659, and Emory# 000002114. Research reported in this publication was supported by the National Institute of General Medical Sciences of the National Institute of Health under award number 5T32GM142623 to J. Art, R01MH115174 to V. Michopoulos, and R01NS114567 to N. Zeltner. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
10 cm standard tissue culture dishesFalcon353003
12 well platesFalcon353043
15 mL conical tubesFisher7200886
24 well platesCorning7200740
4% paraformaldehyde solutionThermo ScientificJ19943-K2
6 well platesFisher ScientificFB012927
accuSpin1RFisher Scientific75003449
Activin ABio-techne338-AC
AF488-donkey α goatinvitrogenA11055
AF555-donkey α rbtinvitrogenA31572
AF647-donkey α minvitrogenA31571
AF647-donkey α rbtinvitrogenA31573
Antibiotic-Antimycotic (100X)Fisher15 240 096 
Basix Polystyrene Serological PipetsFisher14955233
14955234
14955235
14955236
BD Tuberculin SyringesFisher14-826-87
BD Vacutaine Glass Mononuclear Cell Preparation (CPT) TubesFisher Scientific02-685-125PBMC isolating blood collection tubes
BD Vacutainer Plastic Blood Collection Tubes with K2EDTA: Hemogard ClosureFisher Scientific02-657-32anti-coagulent coated blood collection tubes
B-MercaptoethanolFisher21 985 023 
Bovine GelatinSigmaG1393
Brachyury-T antibody polyclonal goat IgGR&DAF2085
CellDrop BFDenovixCellDrop BF
Centrifuge 5702EppendorfEP022628102-1EA
chemically defined lipid concentrateFisherNC9022744
Chir 99021 R&D4423
CO2 incubatorSanyoMCO-20AIC
Cryopreservation Storage SystemCustom Biogenic SystemsV-1500AB
CryoStor CS10Stem Cell Technologies100-1061alternate freezing medium
CytoTune-iPS 2.0 Sendai Reprogramming KitFisherA16517
DexamethasoneSigmaD2915
DMEMFisher11965118
DMEM/F12Fisher11330057
DMSOFisherBP231-1
DPBS 1X W/O CA MG FisherMT21031CM
EDTAFisherAM9262
Erythropoeitin (EPO)Bio-Techne287-TC-500
Essential 6 Medium (E6)FisherA1516401differentiation base 
Essential 8 medium (E8)FisherA1517001hPSC basal medium
EVOS FL microscopeThermoAMF4300
Fetal Bovine SerumVWR45000-734
FGF basic (FGF2)Bio-techne233-FB/CF 
GeltrexFisherA1413202Matrix coating
Gibco MEM Non-Essential Amino Acids Solution (100X)Fisher11140050
GlutamaxFisher35050061L-glutamine substitute 
HeparinStem Cell Technologies7980
Histopaque 1077Sigma10771density gradient solution 1 
HolotransferrinSigmaT0665
Human Stem Cell Factor (SCF)Peprotech300-07-100UG
Insulin like Growth Factor 1 (IGF1)Peprotech100-11-100UG
Interleukin-3 (IL-3)Peprotech200-03-2UG
Isotemp 210 water bathFisher Scientific210
Knockout-Serum-Replacement (KSR)Fisher10828028FBS free supplement 
L-Ascorbic AcidSigmaA4544-100G
LDN193189Stemgent04-0074
L-GlutamineFisher25030081
LymphoprepStem Cell Technologies7801Density gradient solution 2
MatrigelCorningCB-40234Matrix coating
Mouse Embryonic FibroblastsFisherA34964 
Nanog polyclonal goat IgGR&DAF1997-SP
Nunc Biobanking and Cell Culture Cryogenic TubesFisher Scientific12-565-163N
Penicillin/StreptomycinFisher15140122
Purified anti-Pax-6 Antibody rabbit polyclonal IgGBiolegend901301
QBSF-60 Serum Free MediumQuality Biological160-204-101EM base
Recovery Cell Culture Freezing MediumThermo Fisher Scientific12648010alternate freezing medium
rhVitronectin (VTN)FisherA31804
RPMI 1640 MediumFisher11875093
SB431542R&D1614
Sendai virus HN Monoclonal Antibody Mouse IgG2aInvitrogen14649482
Sodium SeleniteSigmaS5261
Sox17 Antibody polyclonal goat IgGR&Daf1924
StemSpan Erythroid Expansion supplementStem Cell Technologies2692Alternate commercial expansion medium supplement
StemSpan SFEM II mediumStem Cell Technologies9605Alternate commercial expansion medium
Ultra Low Temperature FreezerThermo Fisher ScientificTSX60086A
Universal Pipette Tips- FilteredVWR76322-132
76322-134
76322-150
76322-156
XAV939Bio-techne3748/10
Y-27632 DihydrochlorideBioGems1293823

References

  1. Takahashi, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 131 (5), 861-872 (2007).
  2. Ray, A., et al. An overview on promising somatic cell sources utilized for the efficient generation of induced pluripotent stem cells. Stem Cell Rev Rep. 17 (6), 1954-1974 (2021).
  3. Raab, S., Klingenstein, M., Liebau, S., Linta, L. A comparative view on human somatic cell sources for ipsc generation. Stem Cells Int. 2014, 768391(2014).
  4. Sauer, V., et al. Human urinary epithelial cells as a source of engraftable hepatocyte-like cells using stem cell technology. Cell Transplant. 25 (12), 2221-2243 (2016).
  5. Kleiveland, C. R. Peripheral blood mononuclear cells. The Impact of Food Bioactives on Health: in vitro and ex vivo models. , 161-167 (2015).
  6. Quirynen, M., Siawasch, S. aM., Yu, J., Miron, R. J. Essential principles for blood centrifugation. Periodontol 2000. 97 (1), 43-51 (2025).
  7. Perry, J. N., Jasim, A., Hojat, A., Yong, W. H. Procurement, storage, and use of blood in biobanks. Methods Mol Biol. 1897, 89-97 (2019).
  8. Meraviglia, V., et al. Generation of induced pluripotent stem cells from frozen buffy coats using non-integrating episomal plasmids. J Vis Exp. (100), e52885(2015).
  9. Yang, W., et al. iPSC reprogramming from human peripheral blood using Sendai Virus mediated gene transfer. , Stembook. Cambridge (MA). (2008).
  10. Cerneckis, J., Cai, H., Shi, Y. Induced pluripotent stem cells (ipscs): Molecular mechanisms of induction and applications. Signal Transduct Target Ther. 9 (1), 112(2024).
  11. Zhang, X. B. Cellular reprogramming of human peripheral blood cells. Genomics Proteomics Bioinformatics. 11 (5), 264-274 (2013).
  12. guidelines on drawing blood: best practices in phlebotomy. , World Health Organization. Geneva. (2010).
  13. Robb, L. Cytokine receptors and hematopoietic differentiation. Oncogene. 26 (47), 6715-6723 (2007).
  14. Strober, W. Trypan blue exclusion test of cell viability. Curr Protoc Immunol. 111, A3 B 1-A3 B 3 (2015).
  15. Chen, G. Splitting hESC/hiPSC lines with EDTA in feeder free conditions. , Stembook. Cambridge (MA). (2008).
  16. Zeltner, N., Lafaille, F. G., Fattahi, F., Studer, L. Feeder-free derivation of neural crest progenitor cells from human pluripotent stem cells. J Vis Exp. (87), e51609(2014).
  17. Zhang, X., et al. Pax6 is a human neuroectoderm cell fate determinant. Cell Stem Cell. 7 (1), 90-100 (2010).
  18. Lin, Y., Zou, J. Differentiation of cardiomyocytes from human pluripotent stem cells in fully chemically defined conditions. STAR Protoc. 1 (1), (2020).
  19. Technau, U. Brachyury, the blastopore and the evolution of the mesoderm. Bioessays. 23 (9), 788-794 (2001).
  20. Zeltner, N., et al. Capturing the biology of disease severity in a psc-based model of familial dysautonomia. Nat Med. 22 (12), 1421-1427 (2016).
  21. Kanai-Azuma, M., et al. Depletion of definitive gut endoderm in sox17-null mutant mice. Development. 129 (10), 2367-2379 (2002).
  22. Kirkeby, A., Main, H., Carpenter, M. Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update. Cell Stem Cell. 32 (1), 10-37 (2025).
  23. Verma, I., Seshagiri, P. B. Current applications of human pluripotent stem cells in neuroscience research and cell transplantation therapy for neurological disorders. Stem Cell Rev Rep. 21 (4), 964-987 (2025).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Tags

Induced Pluripotent Stem CellsBuffy Coat ReprogrammingPBMC ReprogrammingStem Cell MorphologySendai Virus TransductionStemness Marker NANOGErythroblast DifferentiationImmunofluorescence StainingDensity Gradient IsolationHuman Pluripotent Stem Cells
Reprogramming Induced Pluripotent Stem Cell Lines from Frozen Buffy Coat Samples
Contact Us
Recommend to Library

Privacy

Terms of Use

Policies

Copyright © 2026 MyJoVE Corporation. All rights reserved.